LongevityNext
A measured piece on mTOR, off-label enthusiasm, human evidence, side effects, dosing, and why rapamycin remains both important and unresolved. The piece keeps the focus on evidence, commercial…
Argue that organ-specific risk may be more clinically useful than one whole-body biological-age score. The piece keeps the focus on evidence, commercial logic, and what would make the…
Break down memberships, diagnostics, imaging, lab markups, physician time, coaching, software, and repeat testing. The piece keeps the focus on evidence, commercial logic, and what would make the…
Treat reprogramming as the next major therapeutic frontier, but frame the real product as control, delivery, reversibility, and safety rather than simple rejuvenation. The piece keeps the focus…
Use the NewLimit $435 million financing as a market signal: investors are buying a long-duration option on controllable reprogramming, not a simple proof that rejuvenation medicine is ready.…
The useful question is not whether a longevity platform sounds futuristic. It is whether its claims can be tested against prediction, intervention response, replication, and clinical outcomes.
Recent longevity deals are not funding one grand anti-aging thesis. They are clustering around businesses that make longevity legible as diagnostics, animal-health therapeutics, and platform discovery.
Longevity brands do not get into trouble because they mention healthspan. They get into trouble when prevention language quietly becomes diagnosis, treatment, cure, mitigation, or disease-risk reduction.
Abu Dhabi's healthy longevity medicine framework is not just another wellness initiative. It is an early test of what regulated longevity care might look like when clinics, data…
Compares molecular, organ-level, functional and clinical aging measures by intended use, validation and limits.